If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Tirzepatide: Comparison With Once-Weekly Semaglutide 2 mg
Tirzepatide compared with semaglutide 2 mg has not been studied.
cFAQ
cFAQ
US_cFAQ_TZP306_SEMAGLUTIDE_2MG
en-US
Detailed Information
SURPASS-2 compared tirzepatide with once-weekly semaglutide 1 mg, the highest approved dose of semaglutide available at the time.1,2
Lilly has not conducted and are not currently conducting clinical studies comparing tirzepatide with once-weekly semaglutide 2 mg.2
References
1A study of tirzepatide (LY3298176) versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes (SURPASS-2). ClinicalTrials.gov identifier: NCT03987919. Updated March 11, 2021. Accessed March 23, 2021. https://clinicaltrials.gov/ct2/show/NCT03987919
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
Lilly = Eli Lilly and Company
Date of Last Review: March 23, 2021
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon – Friday, 9am-7pm (EST), excluding holidays